Synchron raises $200M to prepare for brain computer interface launch

Synchron Raises $200M to Advance Brain-Computer Interface

Synchron secured $200 million to speed up pivotal trials and prepare for the commercial release of its Stentrode brain-computer interface (BCI) system. BCIs are devices that interpret brain signals to trigger actions, such as hands-free control of digital technology.

Comparing BCI Technologies

While Elon Musk’s Neuralink implants devices by removing part of the skull, Synchron’s first-generation Stentrode is implanted via a less invasive catheter procedure. Each approach balances the invasiveness of implantation with signal quality.

Despite fewer electrodes, Stentrode enables people with severe paralysis to control personal devices effectively.

Future Developments and Strategy

This Series D funding aims to leverage the current device’s strengths while addressing its limitations. Synchron also plans to develop a next-generation, transcatheter, high-channel whole-brain interface.

Artificial Intelligence Integration

Synchron is expanding its AI team in New York City to develop models that learn from brain data. The company's ultimate objective is to decode thoughts in real time.

Synchron’s goal is to decode thought in real time.

Author's summary: Synchron’s $200M funding will accelerate clinical trials and fuel AI-driven brain signal decoding, aiming for a less invasive, real-time brain-computer interface launch.

more

MedTech Dive MedTech Dive — 2025-11-07

More News